Azacytidine

규격

320-67-2CAS 번호

206-280-2EC 번호

4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-oneIUPAC 명칭

C8H12N4O5화학식

244.2 g/mol분자량

5-azacytidine; Azacitidine; 320-67-2; Azacytidine; Ladakamycin; Mylosar; 5-azacitidine; Azacitidina; Azacitidinum; Antibiotic U 18496; Onureg; U-18496; DTXSID9020116; NSC 102816; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; NSC102816; 5-AZCR; 5 AZC; CHEBI:2038; M801H13NRU; U 18496; U-18,496; 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; DTXCID10116; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; NCI-C01569; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; 5 Azacytidine; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; azacitidine for; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-1,2-dihydro-1,3,5-triazin-2-one; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-1,3,5-triazin-2-one; RefChem:57658; AZACITIDINE AZACITIDINE; L01BC07; 4-Amino-1-beta-D-ribofuranosyl-D-triazin-2(1H)-one; 5'-AZACYTIDINE; Vidaza; Azacitidinum [INN-Latin]; Azacitidina [INN-Spanish]; NSC-102816; C8H12N4O5; 5-AZAC; MFCD00006539; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; WR-183027; NCGC00090851-04; 1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-; 5-Aza-xylo-cytidine; CCRIS 60; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; SMR000857239; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Vidaza (TN); HSDB 6879; 5-aza-CR; SR-01000075662; EINECS 206-280-2; Azacitidine;5-AzaC;Ladakamycin; BRN 0620461; UNII-M801H13NRU; cc-486; Azacitidine (JAN/USAN/INN); Azacitidine [USAN:INN:BAN]; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; 5-Azacytidine?; NS-17; 1-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-amino-1,3,5-tri azin-2-one; CAS-320-67-2; 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; Azacitidine, 5-AzaC; Spectrum_001262; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; AZACITIDINE [MI]; Spectrum2_000786; Spectrum3_001509; Spectrum4_000922; Spectrum5_001166; AZACITIDINE [INN]; AZACITIDINE [JAN]; 5-Azacytidine (Standard); AZACITIDINE [HSDB]; AZACITIDINE [IARC]; AZACITIDINE [USAN]; Epitope ID:613415; MolMap_000062; 4-Amino-1-.beta.-D-ribofuranosyl-s-triazin-2(1H)-one; A 2385; AZACITIDINE [VANDF]; SCHEMBL3741; AZACITIDINE [MART.]; CHEMBL1489; Azacitidine (5-Azacytidine); Lopac0_000035; AZACITIDINE [USP-RS]; AZACITIDINE [WHO-DD]; BSPBio_003157; KBioGR_001444; KBioGR_002556; KBioSS_001742; KBioSS_002565; MLS001333121; MLS001333122; MLS002153249; MLS002548894; DivK1c_000125; SCHEMBL433074; SPECTRUM1502111; SPBio_000892; AZACITIDINE [EMA EPAR]; GTPL6796; orb1225313; orb1308921; BCBcMAP01_000083; HMS500G07; KBio1_000125; KBio2_001742; KBio2_002556; KBio2_004310; KBio2_005124; KBio2_006878; KBio2_007692; KBio3_002657; KBio3_003034; NMUSYJAQQFHJEW-KVTDHHQDSA-; AZACITIDINE [ORANGE BOOK]; pyrimidine antimetabolite: inhibits nucleic acid replication; cMAP_000082; NINDS_000125; GLXC-07091; HMS1921J22; HMS2092D08; HMS2231F15; HMS3259D19; HMS3260G11; Pharmakon1600-01502111; 5-Azacytidine, >=98% (HPLC); Tox21_111032; Tox21_302985; Tox21_500035; BDBM50424715; CCG-39046; EBC-11024; HB1374; HY-10586R; NSC758186; SBB066305; Onureg (CC-486; oral azacitidine); AKOS015896938; Tox21_111032_1; CS-1287; DB00928; LP00035; NA02947; NC00672; NSC-758186; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; IDI1_000125; NCGC00090851-01; NCGC00090851-02; NCGC00090851-03; NCGC00090851-05; NCGC00090851-06; NCGC00090851-07; NCGC00090851-08; NCGC00090851-10; NCGC00090851-14; NCGC00090851-18; NCGC00090851-22; NCGC00090851-28; NCGC00178234-01; NCGC00256541-01; NCGC00260720-01; AS-13697; HY-10586; SRI-10756_10; SRI-10756_12; ST056940; SY023613; DB-006955; SL-000003; A9602; EU-0100035; NS00008631; D03021; EN300-118700; F10504; F492447; Q416451; SR-01000075662-1; SR-01000075662-3; SR-01000075662-7; BRD-K03406345-001-02-1; BRD-K03406345-001-21-1; BRD-K03406345-001-27-8; Z1515383340; 4-Amino-1-ss-D-ribofuranosyl-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-tr iazin-2(1H)-one; Azacitidine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material; 1401238-97-8; 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 5AE; InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1동의어